ストックスクリーナーアプリを入手
17.84
1.77%
0.31
プレマーケット:
17.65
-0.19
-1.07%
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Market Recap: Is Corvus Pharmaceuticals Inc stock forming a cup and handle2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Assessing Corvus Pharmaceuticals (CRVS) Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data - Sahm
Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 - MarketBeat
Corvus Pharmaceuticals at Oppenheimer: Soquelitinib’s Promising Potential By Investing.com - Investing.com Canada
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Yahoo Finance
Corvus Pharma sets virtual Oppenheimer talk, 90-day replay - Stock Titan
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6%Time to Sell? - MarketBeat
Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP - MarketBeat
Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge - Sahm
Is Corvus Pharmaceuticals (CRVS) Still Attractive After A 185% Monthly Surge? - simplywall.st
Corvus Pharmaceuticals (CRVS) price target increased by 128.26% to 35.70 - MSN
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - Investing.com
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options - Nasdaq
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - The Globe and Mail
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum - Sahm
Mizuho Raises Price Target on Corvus Pharmaceuticals to $30 From $20, Keeps Outperform Rating - marketscreener.com
Corvus Soquelitinib Data Spurs Phase 2 Plans And Fuels CRVS Reassessment - Sahm
Aug Selloffs: Why is Corvus Pharmaceuticals Inc. stock going downJuly 2025 Price Swings & Accurate Entry/Exit Alerts - mfd.ru
Will Corvus Pharmaceuticals Inc. benefit from rate cutsPrice Action & Low Risk Growth Stock Ideas - mfd.ru
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet - Your Wyoming Link
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know - Yahoo Finance
10 Big Names Stumbling Hard - Insider Monkey
Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump - Finviz
Latham Watkins Advises Corvus Pharmaceuticals in Upsized Public Offering of Common Stock - Latham & Watkins LLP
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3%Here's What Happened - MarketBeat
Hedge Fund Moves: Is Corvus Pharmaceuticals Inc exposed to political risk2025 Technical Overview & Consistent Income Trade Recommendations - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study - Finviz
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans - Yahoo Finance
Corvus Pharmaceuticals (CRVS) Valuation Check After Positive Soquelitinib Data And Equity Raise - Sahm
What's Driving the Market Sentiment Around Corvus Pharmaceuticals Inc? - Sahm
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - The Manila Times
Corvus Pharmaceuticals raises $201.2 million in upsized public offering By Investing.com - Investing.com South Africa
Corvus rally continues as clinical optimism offsets dilution concerns - Mugglehead Investment Magazine
Corvus Pharmaceuticals raises $201.2 million in upsized public offering - Investing.com
Corvus Pharmaceuticals Closes Upsized Public Offering, Raising Approximately $201.2 Million - Quiver Quantitative
Corvus Pharma raises $201M to support cancer and skin trials - stocktitan.net
Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock By Investing.com - Investing.com Canada
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results - Finviz
Corvus Pharmaceuticals - The Pharma Letter
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering - TipRanks
Corvus Pharmaceuticals Announces Public Offering of Common Stock - TradingView
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains - MarketBeat
10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Are Hitting New Highs - Insider Monkey
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Jefferies raises Corvus Pharmaceuticals stock price target to $42 on strong AD data - Investing.com Canada
Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies - TipRanks
Corvus Pharmaceuticals prices upsized public offering at $22.15 per share By Investing.com - Investing.com Australia
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 - MSN
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):